ストックスクリーナーアプリを入手
1.68
13.51%
0.20
アフターアワーズ：
1.62
-0.06
-3.57%
Marker Therapeutics Inc (MRKR) 最新ニュース
MSN Money - MSN
Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Profit Outlook - simplywall.st
MRKR Q1 2026 Earnings: Narrower Loss Surpasses ExpectationsRevenue Growth Outlook - dars.gov.et
US High Growth Tech Stocks to Watch - simplywall.st
Stock List: Research Stocks from Around the World - GuruFocus
Price to earnings forward of Marker Therapeutics, Inc. – NASDAQ:MRKR - TradingView
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker - The Globe and Mail
MRKR Forecast — Price Target — Prediction for 2027 - TradingView
Marker Therapeutics, Inc. Actuals & Estimates (NASDAQ:MRKR) - TradingView
Price to sales forward of Marker Therapeutics, Inc. – NASDAQ:MRKR - TradingView
Price to book forward of Marker Therapeutics, Inc. – NASDAQ:MRKR - TradingView
GX1 Forecast — Price Target — Prediction for 2027 - TradingView
Marker Therapeutics Inc (MRKR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Marker Therapeutics Inc (MRKR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Marker Therapeutics Inc (MRKR) Institutional Confidence - TradingKey
Marker Therapeutics Inc (MRKR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Marker Therapeutics Inc (MRKR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Marker Therapeutics Inc (MRKR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Marker Therapeutics Inc (MRKR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Marker Therapeutics Inc (MRKR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Marker Therapeutics Holds Steady Near Key Support and Resistance LevelsADD Alert - newsline.com
Marker Therapeutics Inc (MRKR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Exploring 3 High Growth Tech Stocks in US Market - simplywall.st
Marker Therapeutics (MRKR) Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock Inches HigherEPS Growth Report - newsline.com
MRKR Q1 2026 Earnings: Narrower-than-expected loss highlights cost management amid pipeline progressGuidance vs Actual - newsline.com
Marker Therapeutics (MRKR) Holds Steady Above Support as Biotech Sector Shows Mixed SignalsHigh Dividend Factor - newsline.com
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Exploring High Growth Tech Stocks In The US Market - simplywall.st
MRKR Q1 2026 Earnings: Smaller-than-Expected Loss Surprises PositivelyProfit Growth Outlook - newsline.com
MRKR Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineNon-GAAP Earnings - dars.gov.et
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
Pancreatic Cancer Clinical Trial Pipeline Gains Momentum: 170+ - openPR.com
MRKR Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SentimentProfit Inflection Point - dars.gov.et
Mrkr Q1 2026 Earnings: EPS Beats Estimates as Company Advances PipelineFinal Results - The Legal Advocate
US High Growth Tech Stocks To Watch - simplywall.st
Marker Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Biotech Advances PipelinePre-Announcement Alert - The Legal Advocate
MRKRMarker Therapeutics Inc Stock Price and Quote - Finviz
Marker Therapeutics (MRKR) Faces Pressure: Stock Slips 2.1% to $1.4Undervalued Stocks - newsline.com
Marker Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline ProgressesMargin Compression Risk - Newser
Marker Therapeutics Inc. (MRKR) Q1 2026 Earnings: EPS Beat Expectations Amid Development Stage OperationsRevenue Estimate Trend - Newser
Marker Therapeutics Q1 2026 Earnings: Loss Narrows as Clinical Progress ContinuesPost-Earnings Drift - Newser
Marker Therapeutics (MRKR) upgraded to buy: What does it mean for the stock? - MSN
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy - Investing.com
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy By Investing.com - Investing.com Canada
CCORF Maintains Marker Therapeutics(MRKR.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Marker Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Marker Therapeutics (MRKR) narrows Q1 2026 loss but warns on going concern - Stock Titan
Marker Therapeutics, Inc. Q1 2026: Net loss $(3.18M), Diluted EPS $(0.16) — 10-Q Summary - TradingView
MRKR: Net loss improved to $3.2M in Q1 2026, with cash funding expected through Q1 2027 - TradingView
Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Marker Therapeutics (MRKR) Fell -0.82% — Is a Recovery Ahead? 2026-05-15Community Pattern Alerts - Newser
Marker Therapeutics (MRKR) Q4 2025 Earnings: $-0.09 EPS Surges Past $-0.20 EstimatesNew Analyst Coverage - Newser
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
OnCusp Therapeutics Appoints Anthony Kim as Chief Financial Officer - The Manila Times
TradingKey - tradingkey.com
Marker Therapeutics MRKR Q4 2025 loss narrows unexpectedly, beating estimates by 55%; shares tick higher.Crowd Entry Points - Newser
Number of shareholders of Marker Therapeutics, Inc. – NASDAQ:MRKR - TradingView
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):